July 08, 2026 Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio Bio-Techne has expanded its AI-Engineered Designer Protein portfolio to improve consistency and scalability in cell culture workflows. New proteins aim to address variability in advanced therapies, enhancing research and manufacturing processes.
June 29, 2026 Bio-Techne Under Scrutiny: Kahn Swick & Foti Investigates Proposed Sale to Merck KGaA Bio-Techne's proposed sale to Merck KGaA is under investigation by Kahn Swick & Foti, which questions the fairness of the $73.00 per share offer. Shareholders are encouraged to assess their rights as the inquiry unfolds, potentially impacting the sale's outcome.
June 25, 2026 Bio-Techne Corporation Under Investigation Following Acquisition Announcement Bio-Techne Corporation's acquisition by Merck KGaA has prompted an investigation by Halper Sadeh LLC, raising concerns about the fairness of the deal. Shareholders may benefit from increased disclosures and potential compensation if fiduciary duties were breached.
June 25, 2026 Merck KGaA to Acquire Bio-Techne Corp: A Strategic Move in Life Sciences Merck KGaA has announced its acquisition of Bio-Techne Corp, aiming to strengthen its position in the life sciences market. This strategic move will enhance product offerings and foster innovation, benefiting healthcare and research sectors globally.
June 04, 2026 Bio-Techne and Refeyn Revolutionize Bispecific Antibody Characterization Bio-Techne and Refeyn have partnered to create an integrated workflow that streamlines the characterization of bispecific antibodies. This innovative approach significantly enhances efficiency, reduces risks, and enables precise analysis crucial for drug development.
May 06, 2026 Bio-Techne Corp's Q3 2026 Financial Report: Navigating Challenges with Strategic Focus Bio-Techne Corporation's Q3 2026 report shows a 2% decline in net sales to $311.4 million. With strategic focus on core operations and innovation, the company aims for long-term growth despite market challenges.
May 06, 2026 Bio-Techne Corporation Reports Mixed Results for Third Quarter Fiscal 2026 Bio-Techne Corporation reported Q3 fiscal 2026 revenues of $311.4 million, a 2% decline, but a notable increase in GAAP EPS to $0.32. The company sees growth in large pharma, while facing challenges in emerging biotech and academic markets. CEO Kim Kelderman expresses optimism for future opportunities.
May 06, 2026 Bio-Techne Corp Declares Quarterly Dividend: A Strategic Move for Shareholders Bio-Techne Corp has declared a quarterly dividend of $0.08 per share, reflecting its strong financial performance and strategic growth. This decision underscores the company's commitment to returning value to shareholders amidst ongoing market challenges.
May 04, 2026 Bio-Techne Corporation to Showcase Innovations at Bank of America Securities Global Healthcare Conference Bio-Techne Corporation will be presenting at the Bank of America Securities Global Healthcare Conference on May 12, 2026. With a legacy of 50 years in the life sciences sector, the company aims to highlight its advancements and commitment to scientific empowerment.
April 16, 2026 Bio-Techne Corp Unveils Streamlined Brand Architecture to Enhance Customer Navigation Bio-Techne Corporation has restructured its brand architecture to improve customer navigation through its extensive product offerings. The new organization includes three main portfolios: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, each focused on different stages of scientific research and clinical diagnostics.
April 14, 2026 Bio-Techne Corporation to Host Q3 Fiscal 2026 Financial Conference Call Bio-Techne Corporation will host its Q3 Fiscal 2026 financial conference call on May 6, 2026, at 8 AM CDT. Investors can join via dial-in or webcast, with a replay available after the call.
March 25, 2026 Bio-Techne Advances Spatial Biology with New Modular Enhancements Bio-Techne has launched SPYRE Focus Panels and Amplification Kits to enhance its COMET™ suite, providing researchers with improved flexibility and sensitivity. These innovations streamline spatial biology workflows, allowing for deeper analysis of biological data and empowering researchers in their scientific endeavors.
February 24, 2026 Bio-Techne Corporation to Showcase Innovations at Key Investor Conferences Bio-Techne Corporation is set to present at two major investor conferences in March 2026, focusing on its innovations in life sciences and clinical diagnostics. The company aims to enhance investor engagement and showcase its strong market position and growth potential.
February 16, 2026 Bio-Techne's Ella Platform Receives CE-IVD Mark, Enhancing Diagnostic Capabilities in Europe Bio-Techne's Ella platform has received CE-IVD marking, allowing its use in European clinical laboratories. This certification improves diagnostic speed and accuracy, supporting precision medicine through advanced biomarker detection.
February 11, 2026 Bio-Techne Corp Announces Strategic Leadership Changes Bio-Techne Corporation announces significant leadership changes, with Steve Crouse appointed as President of the Diagnostics and Spatial Biology Segment. This transition comes as Dr. Matt McManus steps down, ensuring continuity in innovation and growth within the company.
February 04, 2026 Bio-Techne Corp Announces Quarterly Dividend in Press Release Bio-Techne Corporation has declared a quarterly dividend of $0.08 per share, reflecting its strong financial performance. The dividend will be paid on February 27, 2026, to shareholders on record by February 16, 2026, indicating the company’s commitment to shareholder value amidst its growth strategies in the life sciences sector.
February 04, 2026 Bio-Techne Corporation Reports Flat Revenue but Improved Earnings in Q2 FY2026 Bio-Techne Corporation announced flat revenues of $295.9 million for Q2 FY2026 but showed improved earnings with a GAAP EPS of $0.24. The company’s performance highlights its adaptability and ongoing profitability initiatives despite market challenges.
February 04, 2026 Bio-Techne Corp Reports Steady Q2 Results for 2026, With Strategic Focus on Growth and Innovation Bio-Techne Corporation reported Q2 2026 net sales of $295.8 million, reflecting stable performance in a challenging market. The company focuses on growth through innovation and strategic partnerships while maintaining strong liquidity and operational efficiency.
February 02, 2026 Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with Innovative Synthetic Hydrogel Bio-Techne Corporation introduces Cultrex Synthetic Hydrogel, a synthetic extracellular matrix that enhances 3D stem cell and organoid research. This product minimizes biological variability, supports various applications, and aligns with regulatory innovation goals, ensuring consistent and reliable results in research.
January 28, 2026 Bio-Techne Corp Unveils Simple Plex Ultra-Sensitive Assays on Ella Platform Bio-Techne has launched Simple Plex Ultra-Sensitive Assays on its Ella platform, enabling femtogram-level detection of neurological biomarkers. This innovative technology addresses early detection challenges, improving research capabilities in neurodegenerative diseases.
January 20, 2026 Bio-Techne Corp Announces Upcoming Conference Call for Q2 Fiscal 2026 Results Bio-Techne Corporation will host a conference call on February 4, 2026, to discuss Q2 fiscal 2026 results. Participants can join via phone or webcast, with a replay available afterward. The session is crucial for investors seeking insights into the company's performance and strategies.
December 23, 2025 Bio-Techne Corporation Set to Present at 2026 J.P. Morgan Healthcare Conference Bio-Techne Corporation will present at the 2026 J.P. Morgan Healthcare Conference on January 13. CEO Kim Kelderman will share insights on the company's strategic direction and financial performance, following a successful fiscal 2025 with over $1.2 billion in sales.
December 11, 2025 Bio-Techne Partners with Wyss Center to Propel 3D Multiomics Research Bio-Techne and the Wyss Center have partnered to advance 3D multiomics technology, enabling simultaneous RNA and protein detection in three dimensions. This collaboration aims to enhance understanding of biological systems, improve drug discovery, and reduce reliance on animal models, marking a significant step in ethical research practices.
December 09, 2025 Bio-Techne Corp Unveils Enhanced Leo™ System: A Game Changer in Protein Analysis Bio-Techne has launched the enhanced Leo™ System, revolutionizing protein analysis with dual-channel fluorescence detection. This advanced system improves data throughput and precision, enabling researchers to tackle complex biological questions efficiently.
November 25, 2025 Bio-Techne Corp Set to Showcase Innovations at Upcoming Investor Conferences Bio-Techne Corporation will participate in several key investor conferences in December 2025, showcasing their growth strategies and innovative products. The company's robust performance and market positioning highlight its significant role in the life sciences industry.
November 18, 2025 Bio-Techne Expands Portfolio with AI-Designed NovoBody™ Duo Molecules Bio-Techne has announced a licensing agreement with Monod Bio to commercialize AI-designed NovoBody™ Duo molecules. This partnership aims to advance therapeutic solutions and reinforce Bio-Techne's leadership in AI-enabled healthcare.
November 06, 2025 Bio-Techne Corp Announces Upcoming Presentations at Investor Conferences Bio-Techne Corporation announces its participation in several investor conferences in November 2025, emphasizing transparency and investor engagement. The company will showcase its innovative life science tools and discuss growth opportunities through live webcasts.
November 05, 2025 Bio-Techne Reports First Quarter Fiscal 2026 Results: A Mixed Bag Amid Strategic Changes Bio-Techne's Q1 2026 results show a 1% revenue decline, despite improved earnings. The company is focusing on strategic divestitures to enhance growth in life sciences.
November 05, 2025 Bio-Techne Corp Declares Quarterly Dividend Amid Strong Financial Performance Bio-Techne Corporation has declared a quarterly dividend of $0.08 per share following a strong fiscal performance in 2025, with over $1.2 billion in net sales. The company emphasizes its commitment to shareholders while preparing for future growth amidst industry challenges.
November 05, 2025 Bio-Techne Corp Reports Q1 2026 Results: A Mixed Bag of Performance Bio-Techne Corporation reveals Q1 2026 results with consolidated net sales of $286.5 million, reflecting slight declines in revenue. Despite challenges in Protein Sciences, the company shows optimism with strong performance in Diagnostics. Financial stability remains intact as strategic growth initiatives are underway.
November 04, 2025 Bio-Techne and Nucleai Unveil Groundbreaking AI-Powered Spatial Biology Workflow for Melanoma Treatment Bio-Techne and Nucleai have unveiled groundbreaking findings from the SECOMBIT trial, integrating AI with spatial biology to improve melanoma treatment. This collaboration highlights the significance of immune cell interactions and their spatial distribution, paving the way for more personalized cancer therapies.
November 03, 2025 Bio-Techne Corporation Announces $300,000 G-Rex® Grant Awarded to Sonoma Biotherapeutics Bio-Techne Corporation has awarded a $300,000 G-Rex grant to Sonoma Biotherapeutics to advance the manufacturing of gene-modified Treg therapies. This grant will facilitate the transition to commercially viable production methods, enhancing treatment options for autoimmune diseases.
October 28, 2025 Bio-Techne Unveils ProximityScope™ Assay to Transform Spatial Biology Research Bio-Techne has introduced the ProximityScope assay, revolutionizing spatial biology by enabling visualization of protein-protein interactions at subcellular resolution. This innovation integrates seamlessly with the BOND RX platform and promises significant advancements in therapeutic research and protein interaction studies.
October 23, 2025 Bio-Techne Collaborates on G-Rex Grants to Propel Pediatric Cell Therapy Initiatives Bio-Techne and partners have awarded $375,000 in G-Rex Grants to Children's National Hospital for groundbreaking pediatric cell therapy projects. Key initiatives include innovative CAR-T cell manufacturing and new treatments for solid tumors, aiming to transform pediatric oncology care.
October 15, 2025 Bio-Techne Corporation to Announce First Quarter Fiscal 2026 Results Bio-Techne Corporation will announce its Q1 fiscal 2026 results on November 5, 2025, at 8:00 a.m. CST, with a conference call for investors and analysts. The company, a leader in life sciences, aims to provide insights into its financial performance and strategic direction amid ongoing market challenges.
October 15, 2025 Bio-Techne Partners with Saguaro Biosciences to Enhance Live-Cell Imaging Capabilities Bio-Techne and Saguaro Biosciences have formed a strategic partnership to distribute non-toxic live-cell imaging reagents, meeting the growing demand in drug discovery. This collaboration enhances accessibility for researchers and emphasizes the importance of advanced tools in life sciences.
October 09, 2025 Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Fuel Genetic Testing Innovations Bio-Techne has expanded its partnership with Oxford Nanopore Technologies to enhance genetic testing capabilities. This collaboration aims to accelerate the development of new diagnostic solutions, focusing on heritable genetic disorders, and is set to progress through 2032.
September 26, 2025 Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications Bio-Techne has unveiled advancements in its spatial biology portfolio, enhancing diagnostic capabilities with RNAscope™ and COMET™ technologies. These innovations will be showcased at the NSH Convention and promise to improve the integration of research with clinical applications, particularly in precision medicine.
September 24, 2025 Bio-Techne Corp Unveils 2025 Sustainability Report: A Commitment to Health and Planet Bio-Techne's 2025 Sustainability Report emphasizes the company's dedication to health and environmental stewardship. Notable achievements include significant emission reductions and advancements in medical science, reflecting a commitment to responsible innovation and sustainable practices.
September 09, 2025 Bio-Techne Corp Partners in $2 Million G-Rex Grants to Propel Cell and Gene Therapy in California Bio-Techne Corporation announced its collaboration in a $2 million G-Rex Grant Program aimed at enhancing cell and gene therapy manufacturing in California. Eight grants have been awarded to support innovative projects, reinforcing California's leadership in CGT and providing exclusive access to advanced manufacturing resources.
August 27, 2025 Bio-Techne Announces Upcoming Investor Presentations: A Deep Dive into the Company’s Strategic Engagement Bio-Techne Corporation has announced its schedule for investor presentations at major healthcare conferences in September 2025. These events will provide insights into the company's innovations, financial performance, and strategic direction.
August 22, 2025 Bio-Techne Corp Reports Fiscal 2025 Annual Results: A Year of Growth Amid Challenges Bio-Techne Corporation's fiscal 2025 results show a 5% increase in consolidated net sales to $1.2 billion, driven by growth in Protein Sciences. However, net earnings fell by 56% due to non-recurring charges. The company aims for continued growth through strategic acquisitions and capital investments.
August 14, 2025 Bio-Techne Corporation Collaborates on $300,000 G-Rex® Grant to Enhance CAR T-Cell Manufacturing Bio-Techne Corporation has partnered with ScaleReady, Wilson Wolf, and CellReady to enhance CAR T-cell manufacturing with a $300,000 G-Rex Grant. This collaboration aims to develop a modular platform for cell and gene therapy, improving efficiency and scalability in treatment production.
August 06, 2025 Bio-Techne Corporation Declares Dividend, Reflecting Strong Fiscal Performance Bio-Techne Corporation has declared a quarterly dividend of $0.08 per share, reflecting its strong fiscal year 2025 performance with $1.2 billion in net sales. The company emphasizes ongoing evaluations for future dividends, showcasing its commitment to shareholder value.
August 06, 2025 Bio-Techne Reports Mixed Results in Fourth Quarter of Fiscal 2025 Bio-Techne Corporation reported a 4% increase in net sales for Q4 2025, but faced a significant decline in GAAP earnings. The strategic divestiture of its Exosome Diagnostics business aims to enhance profitability and focus on high-growth areas. Despite challenges, the company remains optimistic about future growth opportunities.
August 05, 2025 Bio-Techne Corp Announces Strategic Divestiture of Exosome Diagnostics Bio-Techne Corp has announced the divestiture of its Exosome Diagnostics business to Mdxhealth SA, including the ExoDx Prostate test. This strategic move aims to enhance Bio-Techne's focus on high-margin products within life sciences and strengthen Mdxhealth's position in prostate cancer diagnostics.
August 05, 2025 Bio-Techne Corp Partners with Sidra Medicine to Advance CAR-T Cell Therapy Bio-Techne collaborates with Sidra Medicine to advance CAR-T cell therapy for pediatric cancer with a $100,000 G-Rex Grant. This initiative aims to improve treatment outcomes and manufacturing processes for young patients.
July 31, 2025 Bio-Techne Corporation Partners in $665,000 G-Rex Grant for Innovative Cancer Therapies Bio-Techne Corporation collaborates with ScaleReady and Wilson Wolf to fund $665,000 in grants for cancer and rare disease research at the University of Minnesota. Three researchers will develop innovative therapies, including CAR NK cell therapy for ovarian cancer and TIL therapy for solid tumors.
July 17, 2025 Bio-Techne Corp to Announce Fourth Quarter and Fiscal 2025 Financial Results Bio-Techne Corporation will hold a conference call on August 6, 2025, to discuss its fourth quarter and fiscal 2025 financial results. This event is crucial for investors seeking insights into the company's performance and future strategies.
July 15, 2025 Bio-Techne Forms Strategic Partnership with Spear Bio to Enhance Biomarker Detection for Neurological Research Bio-Techne has formed a strategic partnership with Spear Bio to enhance biomarker detection, focusing initially on Alzheimer's disease. Utilizing advanced immunoassay technology, this collaboration aims to improve early detection and treatment outcomes in neurodegenerative research.
July 14, 2025 Bio-Techne's Simple Western™ Technology Key to FDA Approval of ZEVASKYN™ Bio-Techne's Simple Western Technology was crucial in achieving FDA approval for ZEVASKYN, the first autologous gene therapy for RDEB. This advancement offers new hope for patients suffering from this debilitating genetic disorder, showcasing the importance of innovative technologies in modern medicine.
June 24, 2025 Bio-Techne and USP Collaboration: A Game Changer in Monoclonal Antibody and Gene Therapy Development Bio-Techne and USP's new collaboration focuses on improving the development of monoclonal antibodies and gene therapies through stringent quality standards. This partnership aims to address challenges in the biopharmaceutical landscape while ensuring patient safety and effective therapeutic outcomes.
June 10, 2025 Bio-Techne Partners to Support CAR-T Cell Manufacturing in India Bio-Techne has partnered with ScaleReady and Wilson Wolf to support Immuneel Therapeutics in improving CAR-T cell manufacturing in India. This initiative, backed by a $150,000 grant, aims to address the rising demand for effective cancer treatments amid a growing health crisis in the country.
May 29, 2025 Bio-Techne Corp Set to Showcase Innovations at Key Investor Conferences Bio-Techne Corporation is set to showcase its innovations at key investor conferences in June 2025, including the William Blair and Jefferies conferences. These events will provide insights into the company's strategic direction and advancements in life sciences, reflecting its commitment to transparency and growth.
May 14, 2025 Bio-Techne Corporation Partners in Significant G-Rex Grant Awards to Enhance Cell and Gene Therapy Research Bio-Techne Corporation has announced $1,025,000 in G-Rex Grants to enhance cell and gene therapy research at USC and CHLA. Key projects include advancements in CAR-T cell therapies and new therapeutic approaches for pediatric cancers, highlighting the program's potential to improve treatment outcomes.
May 12, 2025 Bio-Techne Showcases Cutting-Edge Solutions at ASGCT 2025 Bio-Techne Corporation will showcase innovative solutions at ASGCT 2025, including a new RNAscope workflow and the Simple Western Leo™ System. The company emphasizes its commitment to advancing gene therapy development through expert discussions and pioneering technologies.
May 08, 2025 Bio-Techne Corporation Set to Present at BofA Securities 2025 Health Care Conference Bio-Techne Corporation's CEO Kim Kelderman will present at the BofA Securities 2025 Health Care Conference, showcasing the company’s innovations and strategic direction. Investors can access the presentation live on the company’s website, highlighting its role in advancing life sciences.
May 08, 2025 Bio-Techne Corp: Q3 2025 Financial Report Highlights Operational Growth Amid Challenges Bio-Techne Corporation's Q3 2025 report reveals a 4% increase in net sales, driven by its Protein Sciences segment. Despite challenges like arbitration costs, the company remains optimistic about future growth and innovation in biotechnology.
May 07, 2025 Bio-Techne Corp Announces Dividend and Share Repurchase Program Bio-Techne Corporation has declared a quarterly dividend of $0.08 and approved a $500 million share repurchase program. These initiatives reflect the company's strong financial health and dedication to enhancing shareholder value while navigating the life sciences market.
May 07, 2025 Bio-Techne Reports Third Quarter Fiscal 2025 Results: Growth Amid Challenges Bio-Techne Corporation has reported a 6% increase in organic revenue for Q3 2025, with strong performance in its Protein Sciences segment. Despite challenges, the company improved its operating margins and remains hopeful for future growth.
May 06, 2025 Bio-Techne Corporation Partners in $300,000 G-Rex® Grant Award to A2 Biotherapeutics Bio-Techne Corporation has partnered with A2 Biotherapeutics and ScaleReady to award a $300,000 G-Rex Grant aimed at enhancing cell therapy manufacturing. This collaboration will support A2's innovative CAR-T cell pipeline, leveraging the G-Rex platform's modular capabilities for scalable production.
April 29, 2025 Bio-Techne Corp Partners in $200,000 G-Rex® Grant Award to March Biosciences Bio-Techne Corporation has partnered with ScaleReady and Wilson Wolf Manufacturing to award a $200,000 G-Rex Grant to March Biosciences. This grant aims to support the manufacturing of MB-105, a CAR-T cell therapy for T-cell lymphomas, streamlining its production process and addressing critical medical needs.
April 24, 2025 Bio-Techne Unveils Early Access Program for Groundbreaking Protein Proximity Detection Technology Bio-Techne Corporation has introduced an Early Access Program for its innovative protein proximity detection technology, enhancing spatial biology research. This assay allows researchers to visualize protein interactions within tissues, promising significant advancements in understanding disease mechanisms.
April 23, 2025 Bio-Techne to Showcase Cutting-Edge Solutions at AACR 2025 Bio-Techne Corporation will showcase its extensive oncology research portfolio at the AACR 2025 Annual Meeting in Chicago. Attendees can explore innovative products, engage in networking events, and attend insightful presentations that highlight advancements in cancer therapeutics and multiomic solutions.
April 15, 2025 Bio-Techne Corporation to Announce Third Quarter Fiscal 2025 Financial Results Bio-Techne Corporation will announce its financial results for Q3 2025 on May 7, 2025. The call will provide insights into the company's performance and future strategies in the life sciences sector, attracting investor interest.
April 02, 2025 Bio-Techne Corporation Expands Partnership with Leica Biosystems to Enhance Spatial Multiomics Bio-Techne Corporation expands its partnership with Leica Biosystems to enhance spatial biology research through the RNAscope™ Multiomic LS Assay. This collaboration introduces protease-free workflows and automation, promising to elevate research capabilities and accelerate scientific discoveries across various disciplines.
March 26, 2025 Bio-Techne Corp Expands European Footprint with New Customer Experience Centre in Düsseldorf Bio-Techne Corporation is opening a new Customer Experience Centre in Düsseldorf in summer 2026 to enhance customer engagement in the EMEA region. The centre will feature advanced technologies like the Leo™ System and COMET™ Platform, supporting the company’s growth strategy and commitment to innovation in life sciences.
March 24, 2025 Bio-Techne Unveils Innovations in Biomarker Detection at USCAP 2025 Bio-Techne Corporation unveils its RNAscope technology at the USCAP 2025 meeting, emphasizing advancements in biomarker detection. Leading pathologists will discuss the impact of this technology on diagnostics and patient care, showcasing its potential to improve turnaround times and accuracy.
March 10, 2025 Bio-Techne Corp Launches Leo: A Game-Changer in Protein Analysis Bio-Techne Corp has launched the Leo System, a cutting-edge protein analysis tool that increases sample throughput and speeds up research processes. With advanced precision and regulatory compliance features, Leo is set to support a variety of applications in the biotech field, offering researchers a reliable solution for their analytical needs.
March 03, 2025 Bio-Techne Launches Innovative Carrier Screening Genetic Panel Bio-Techne has launched the AmplideX® Nanopore Carrier Plus Kit, a groundbreaking tool for carrier screening developed with Oxford Nanopore Technologies. This innovative kit simplifies testing by addressing challenges of traditional sequencing methods, enhancing data quality and efficiency for laboratories.
March 02, 2025 SWOT Analysis of Bio-Techne Corp in 2025 This SWOT analysis of Bio-Techne Corp provides insights into its strengths like brand reputation and innovation, weaknesses such as supplier dependency, and opportunities in emerging markets. It also highlights threats from competition and economic uncertainties, guiding strategic planning for the future.
February 27, 2025 Bio-Techne Set to Showcase Innovations at Upcoming Investor Conferences Bio-Techne Corporation will showcase its latest innovations at three major investor conferences in March 2025. These presentations will provide insights into the company's product offerings and strategic initiatives, aimed at reinforcing its leadership in the life sciences sector.
February 20, 2025 Bio-Techne Expands RNAscope Probe Portfolio to Propel Spatial Biology Research Bio-Techne has launched an expanded RNAscope probe portfolio, featuring over 70,000 unique probes for spatial biology research. This advancement enhances understanding of disease pathology and supports the development of precision medicine.
February 18, 2025 Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System Bio-Techne has launched its GMP TcBuster non-viral genome engineering system, improving gene editing for cell therapies like CAR-T. This innovative technology offers significant advantages over traditional methods, including cost reduction and enhanced efficiency, positioning Bio-Techne as a leader in the field.
February 06, 2025 Bio-Techne Corp. Reports Strong Q2 2025 Financial Results Bio-Techne Corporation reported robust financial results for Q2 2025, with a 9% increase in net sales to $297 million and a rise in net income to $34.89 million. The company continues to excel in its Protein Sciences and Diagnostics segments, despite facing challenges in personnel and regulatory landscapes.
February 05, 2025 Bio-Techne Reports Strong Second Quarter Results for Fiscal 2025 Bio-Techne Corporation's second quarter results for fiscal 2025 reveal a 9% increase in net sales, totaling $297 million. The company also improved its earnings per share and operating margins, highlighting its strong performance in the biopharma market.
February 05, 2025 Bio-Techne Corporation Declares Quarterly Dividend Amid Strong Fiscal Performance Bio-Techne Corporation has announced a quarterly dividend of $0.08 per share, reflecting strong financial results for the fiscal year 2024. The company remains dedicated to returning value to shareholders, with future dividends to be evaluated quarterly. Investors are encouraged to consider potential risks as Bio-Techne navigates the biotechnology landscape.
November 05, 2024 Bio-Techne Corp. Reports Q1 2025 Financial Results: A Mixed Bag Amidst Growth Bio-Techne Corporation's Q1 2025 report reveals a 5% increase in net sales to $289.5 million, but net earnings fell sharply to $33.6 million. The Diagnostics segment thrived with 14% growth, while Protein Sciences faced margin pressures. Investors will watch upcoming strategies closely.
August 22, 2024 Bio-Techne Corp. Reports Strong 2024 Performance Amid Strategic Acquisitions Bio-Techne Corp. reported a 2% increase in net sales for fiscal 2024, driven by strategic acquisitions and robust growth in Diagnostics and Genomics. Despite challenges, the company remains committed to innovation and expanding its market presence.
May 06, 2024 Bio-Techne Corp. Reports Q3 2024 Results: Growth Amidst Challenges Bio-Techne Corp. has reported a 3% increase in Q3 2024 sales, driven by its Protein Sciences segment. Despite growth, the company faces rising costs and increased competition, impacting profitability and margins. Future challenges include integration complexities from recent acquisitions and supply chain issues.
